S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

ChemoCentryx Stock Forecast, Price & News

-0.81 (-2.43%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.02 million shs
Average Volume
1.44 million shs
Market Capitalization
$2.27 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

ChemoCentryx logo

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$64.89 million
Book Value
$5.57 per share


Net Income
$-55.36 million
Net Margins
Pretax Margin




Free Float
Market Cap
$2.27 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.13 out of 5 stars

Medical Sector

483rd out of 1,405 stocks

Pharmaceutical Preparations Industry

229th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

Is ChemoCentryx a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ChemoCentryx stock.
View analyst ratings for ChemoCentryx
or view top-rated stocks.

How has ChemoCentryx's stock price been impacted by Coronavirus (COVID-19)?

ChemoCentryx's stock was trading at $41.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CCXI stock has decreased by 21.8% and is now trading at $32.50.
View which stocks have been most impacted by COVID-19

Are investors shorting ChemoCentryx?

ChemoCentryx saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 4,920,000 shares, a decrease of 18.5% from the November 15th total of 6,040,000 shares. Based on an average trading volume of 4,830,000 shares, the short-interest ratio is presently 1.0 days. Currently, 8.6% of the company's stock are short sold.
View ChemoCentryx's Short Interest

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for ChemoCentryx

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative net margin of 353.41% and a negative trailing twelve-month return on equity of 34.78%. During the same quarter in the prior year, the company earned ($0.35) earnings per share.
View ChemoCentryx's earnings history

What price target have analysts set for CCXI?

6 equities research analysts have issued 1 year price targets for ChemoCentryx's stock. Their forecasts range from $38.00 to $110.00. On average, they anticipate ChemoCentryx's stock price to reach $75.00 in the next year. This suggests a possible upside of 130.8% from the stock's current price.
View analysts' price targets for ChemoCentryx
or view top-rated stocks among Wall Street analysts.

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the following people:
  • Thomas J. Schall, Chairman, President & Chief Executive Officer
  • Tausif Butt, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
  • Susan M. Kanaya, Chief Financial Officer, Secretary & Director
  • Rita I. Jain, Chief Medical Officer, Executive Director & EVP
  • Sangita Ghosh, Senior Vice President-Technical Operations

What is Thomas J. Schall's approval rating as ChemoCentryx's CEO?

10 employees have rated ChemoCentryx CEO Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among ChemoCentryx's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ChemoCentryx own?

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $32.50.

How much money does ChemoCentryx make?

ChemoCentryx has a market capitalization of $2.27 billion and generates $64.89 million in revenue each year. The biopharmaceutical company earns $-55.36 million in net income (profit) each year or ($1.74) on an earnings per share basis.

How many employees does ChemoCentryx have?

ChemoCentryx employs 133 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is www.chemocentryx.com.

Where are ChemoCentryx's headquarters?

ChemoCentryx is headquartered at 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at [email protected], or via fax at 650-210-2910.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.